Tadenan® (Tadenan® )

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePlums of African bark extractPlums of African bark extract
Similar drugsTo uncover
  • Tadenan®
    capsules inwards 
    Laboratories SA Fournier.     France
  • Trianol®
    capsules inwards 
    Lek dd     Slovenia
    • Dosage form: & nbspcapsules
    Composition:

    Active substance:

    Plums of African bark extract thick (Pygeum africanum Hook) - 50 mg Excipients: peanut butter - 150 mg

    Capsule shell: gelatin - 89 mg, glycerol - 38 mg, titanium dioxide - 3.6 mg, copper chlorophyllin sodium 0.005 mg

    Description:

    Soft gelatin capsules of oval shape of size No. 4, consisting of two longitudinal halves, each of which has an opaque white / light green color. The contents of capsules is an oily liquid of brown color.

    Pharmacotherapeutic group:treatment of benign prostatic hyperplasia of plant origin
    ATX: & nbsp

    G.04.C.X   Other drugs for the treatment of benign prostatic hyperplasia

    Pharmacodynamics:

    An agent that reduces the proliferation of prostate cells. The action is determined by the antiproliferative effect on fibroblasts, stimulated b-FGF (the main growth factor of fibroblasts).

    The drug does not affect the activity of the hormones of the male reproductive system.

    Pharmacokinetics:

    Data on pharmacokinetic properties are not available, since the effectiveness of the African plum bark extract can not be attributed to its one or more components.

    Indications:

    Treatment of functional disorders urinary system with benign prostatic hyperplasia (adenoma).

    Contraindications:

    Hypersensitivity to extracts crust of African plum or other plants of the same family as the plum African (African Plum), peanut butter oil or soy, and other components of the drug.

    Age to 18 years.

    Carefully:

    Due to the fact that the drug contains peanut butter, there is a risk allergic reactions, including severe anaphylactic reaction in people with peanut allergy.

    The drug should be used under the usual supervision of a doctor and examination of the prostate, taking into account the patient's state of health and risk factors.

    Therapy with Tadenan® does not replace surgical intervention, if necessary.

    Information regarding renal or hepatic failure is absent.

    Pregnancy and lactation:

    This medication is not intended for women.

    In animal studies, the drug did not affect the reproductive function of males.

    Dosing and Administration:

    Inside.1 capsule (50 mg) 2 times a day, morning and evening, preferably before meals. The daily dose is 100 mg.

    The course of treatment is usually 6 weeks and can be increased up to 8 weeks. If necessary, a second course of treatment can be prescribed.

    Side effects:

    The most frequent reported side effects are gastrointestinal disorders, such as nausea, constipation, and diarrhea.

    During the post-marketing application, the following adverse effects were reported. Messages were of a spontaneous nature, and for an accurate assessment of the frequency of the cases of available data is not enough.

    From the gastrointestinal tract:

    Nausea, constipation, diarrhea.

    From the immune system:

    Generalized allergic reactions, urticaria.


    Overdose:

    Specific symptoms of overdose are unknown. Symptomatic treatment is recommended.

    Interaction:

    Interaction studies have not been conducted.

    Special instructions:

    Due to the fact that the preparation contains peanut butter, there is a risk of allergic reactions, including severe anaphylactic reaction in people with peanut allergy.

    Use of the drug should occur under the usual supervision of a doctor and a prostate examination, taking into account the patient's health and risk factors.

    Therapy by Tadenan does not replace surgical intervention, if necessary.

    Information regarding renal or hepatic insufficiency is absent.

    Effect on the ability to drive transp. cf. and fur:

    Studies on the effect on the ability to drive vehicles and mechanisms have not been carried out.

    Form release / dosage:

    Capsules 50 mg.


    Packaging:

    10 capsules in PVC / Al blister. For 1, 2 or 3 blisters in a cardboard pack together with instructions for use.

    For 30 capsules in PVC / Al blister. For 1 or 2 blisters in a cardboard pack together with instructions for use.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children!

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N014669 / 01
    Date of registration:17.03.2008
    The owner of the registration certificate:Laboratories SA Fournier.Laboratories SA Fournier. France
    Manufacturer: & nbsp
    Representation: & nbspABBOTT LABORATORIES LLC ABBOTT LABORATORIES LLC Russia
    Information update date: & nbsp06.08.2015
    Illustrated instructions
      Instructions
      Up